$IOVA
IOVANCE BIOTHERAPEUTICS, INC.

2015 Q2 Form 10-Q Financial Statement

#000114420415029130 Filed on May 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.820M $1.470M $1.070M
YoY Change 438.03% 37.38% 1088.89%
% of Gross Profit
Research & Development $4.055M $2.398M $302.7K
YoY Change 1026.39% 692.3% 12.1%
% of Gross Profit
Depreciation & Amortization $240.0K $190.0K $20.00K
YoY Change 850.0%
% of Gross Profit
Operating Expenses $6.440M $5.298M $2.260M
YoY Change 205.21% 134.48% 222.79%
Operating Profit -$6.440M -$5.298M
YoY Change
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$6.370M -$5.300M -$2.260M
YoY Change 201.9% 134.51% 115.24%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.367M -$5.298M -$2.260M
YoY Change 201.75% 134.42% 115.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$119.1K -$140.7K -$108.7K
COMMON SHARES
Basic Shares Outstanding 45.03M shares 44.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.3M $111.3M $18.00M
YoY Change 507.03% 518.33%
Cash & Equivalents $12.56M $111.3M $17.94M
Short-Term Investments $92.30M $0.00
Other Short-Term Assets $400.0K $100.0K $100.0K
YoY Change 300.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $112.7M $111.4M $18.10M
YoY Change 509.27% 515.52%
LONG-TERM ASSETS
Property, Plant & Equipment $2.025M $2.128M $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.025M $2.128M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $112.7M $111.4M $18.10M
Total Long-Term Assets $2.025M $2.128M $0.00
Total Assets $114.7M $113.5M $18.10M
YoY Change 520.21% 527.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.157M $1.107M $300.0K
YoY Change 189.23% 269.12% -76.92%
Accrued Expenses $623.8K $717.8K $800.0K
YoY Change -10.89% -10.27% -80.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.866M $1.911M $1.100M
YoY Change 55.52% 73.7% -91.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $200.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.866M $1.911M $1.100M
Total Long-Term Liabilities $0.00 $0.00 $200.0K
Total Liabilities $1.900M $1.900M $1.300M
YoY Change 58.33% 46.15% -89.43%
SHAREHOLDERS EQUITY
Retained Earnings -$88.23M -$81.86M
YoY Change
Common Stock $1.964K $1.870K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.9M $111.6M $16.80M
YoY Change
Total Liabilities & Shareholders Equity $114.7M $113.5M $18.10M
YoY Change 520.21% 527.28%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$6.367M -$5.298M -$2.260M
YoY Change 201.75% 134.42% 115.24%
Depreciation, Depletion And Amortization $240.0K $190.0K $20.00K
YoY Change 850.0%
Cash From Operating Activities -$4.500M $3.459M -$2.270M
YoY Change 240.91% -252.36% 656.67%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K $782.0K $3.437K
YoY Change 1300.0% 22652.4%
Acquisitions
YoY Change
Other Investing Activities -$99.76M $0.00 $0.00
YoY Change
Cash From Investing Activities -$99.90M -$780.0K $0.00
YoY Change 998900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $68.31M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.670M 70.61M 540.0K
YoY Change 211.54% 12975.93% 80.0%
NET CHANGE
Cash From Operating Activities -4.500M $3.459M -2.270M
Cash From Investing Activities -99.90M -780.0K 0.000
Cash From Financing Activities 5.670M 70.61M 540.0K
Net Change In Cash -98.73M $3.459M -1.730M
YoY Change -20248.98% -299.92%
FREE CASH FLOW
Cash From Operating Activities -$4.500M $3.459M -$2.270M
Capital Expenditures -$140.0K $782.0K $3.437K
Free Cash Flow -$4.360M $2.677M -$2.273M
YoY Change 232.82% -217.74% 657.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
44845087 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113537586 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46506847 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3694 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3694 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
5694 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44871888 shares
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
919350 USD
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44871888 shares
CY2015Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3287026 USD
CY2014Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1956852 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2011033 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
302662 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
5298059 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2259514 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5298059 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2259514 USD
CY2014Q4 lbio Common Stock To Be Issued Value
CommonStockToBeIssuedValue
245153 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193239795 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121160415 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81859953 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76561894 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
111626869 USD
CY2015Q1 us-gaap Revenues
Revenues
USD
CY2014Q1 us-gaap Revenues
Revenues
USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1467753 USD
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33750188 shares
CY2014Q4 lbio Common Stock To Be Issued Shares
CommonStockToBeIssuedShares
303125 shares
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111280443 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44909147 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
128883 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
66134 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
111409326 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44975281 USD
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
289672 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
104223 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2128260 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1531566 USD
CY2015Q1 us-gaap Assets
Assets
113537586 USD
CY2014Q4 us-gaap Assets
Assets
46506847 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1107370 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1248413 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
717847 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
327847 USD
CY2015Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
85500 USD
CY2014Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
85500 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1910717 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1661760 USD
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
5694 shares
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
4 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
6 USD
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33750188 shares
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
1870 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1407 USD
CY2015Q1 lbio Common Stock To Be Issued Shares
CommonStockToBeIssuedShares
303125 shares
CY2015Q1 lbio Common Stock To Be Issued Value
CommonStockToBeIssuedValue
245153 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37678662 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20798229 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
1017308 USD
CY2015Q1 lbio Common Stock Issued Upon Exercise Of Warrants Amount
CommonStockIssuedUponExerciseOfWarrantsAmount
2304250 USD
CY2015Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
USD
CY2015Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
68307838 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
450445 USD
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
185449 USD
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
16565 USD
CY2015Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1017308 USD
CY2014Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
901650 USD
CY2015Q1 lbio Fair Value Of Vested Warrants Granted For Services
FairValueOfVestedWarrantsGrantedForServices
450445 USD
CY2014Q1 lbio Fair Value Of Vested Warrants Granted For Services
FairValueOfVestedWarrantsGrantedForServices
17700 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
62749 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-49625 USD
CY2015Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
248957 USD
CY2014Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-993389 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3458649 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2267363 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
782143 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3437 USD
CY2015Q1 lbio Proceeds From Issuance Of Common Stock Upon Conversion Of Warrants
ProceedsFromIssuanceOfCommonStockUponConversionOfWarrants
2304250 USD
CY2014Q1 lbio Proceeds From Issuance Of Common Stock Upon Conversion Of Warrants
ProceedsFromIssuanceOfCommonStockUponConversionOfWarrants
542500 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
68307838 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
70612088 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
542500 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
66371296 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1728300 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19672177 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17943877 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
USD
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
USD
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
USD
CY2014Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32200000 USD
CY2013Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23300000 USD
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">1-for-100</div>
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3458649 USD
CY2015Q1 lbio Working Capital
WorkingCapital
109498609 USD
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2015Q1 us-gaap Share Price
SharePrice
8.00
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
68300000 USD
CY2014 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6000000 shares
CY2014Q4 us-gaap Share Price
SharePrice
5.75
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45029692 shares
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
507113 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.20
CY2015Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1000000 shares
CY2015Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
2000 shares
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.</p></div>
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><b><i>Concentrations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company maintains cash balances at one bank. As of March 31, 2015, the Company's cash balances were in excess of insured limits maintained at the bank. Management believes that the financial institution that holds the Company's cash is financially sound and, accordingly, minimal credit risk exists.</p></div>
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
72651 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
6.20
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
579764 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.20
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1017308 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
901650 USD
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8665475 USD
CY2015Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2304250 USD
CY2015Q1 lbio Estimated Benchmark Payments For Products
EstimatedBenchmarkPaymentsForProducts
36300000 USD
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Lion Biotechnologies, Inc.
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001425205
CY2015Q1 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><br/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><b><font style="text-decoration: underline;">NOTE 6. LEGAL PROCEEDINGS</font></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">On April 23, 2014, the Company received a subpoena from the Securities Exchange Commission (the &#147;SEC&#148;) that stated that the staff of the SEC is conducting an investigation <i><font style="text-decoration: underline;">In the Matter of Galena Biopharma, Inc. File No. HO 12356</font></i> <i>(now known as &#147;<font style="text-decoration: underline;">In the Matter of Certain Stock Promotions</font>&#148;) </i>and that the subpoena was issued to the Company as part of the foregoing investigation. The SEC's subpoena and accompanying letter do not indicate whether the Company is, or is not, under investigation. We have fully cooperated with the SEC and as of November 2014, we had completed production of documents in response to the subpoena. To date, The SEC has not requested any further action from the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The subpoena requires the Company to give the SEC, among other materials, all communications between anyone at the Company and certain persons and entities (which include investor-relations firms and persons associated with the investor-relations firms), all documents related to the listed persons and entities, all articles regarding the Company posted on certain equity research or other financial websites, and documents and communications related to individuals who post or have posted articles regarding the Company on equity research or other financial websites.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">There are no other pending legal proceedings to which the Company is a party or of which its property is the subject.</p> </div>

Files In Submission

Name View Source Status
0001144204-15-029130-index-headers.html Edgar Link pending
0001144204-15-029130-index.html Edgar Link pending
0001144204-15-029130.txt Edgar Link pending
0001144204-15-029130-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lbio-20150331.xml Edgar Link completed
lbio-20150331.xsd Edgar Link pending
lbio-20150331_cal.xml Edgar Link unprocessable
lbio-20150331_def.xml Edgar Link unprocessable
lbio-20150331_lab.xml Edgar Link unprocessable
lbio-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v409271_10q.htm Edgar Link pending
v409271_ex31-1.htm Edgar Link pending
v409271_ex31-2.htm Edgar Link pending
v409271_ex32-1.htm Edgar Link pending
v409271_ex32-2.htm Edgar Link pending